Clinical Trials Logo

Thymoma Type B3 clinical trials

View clinical trials related to Thymoma Type B3.

Filter by:
  • None
  • Page 1

NCT ID: NCT04710628 Active, not recruiting - Thymoma Type B3 Clinical Trials

Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents

PECATI
Start date: September 21, 2021
Phase: Phase 2
Study type: Interventional

This is a multicentric, open-label, single arm phase II study to evaluate the efficacy and safety of the combination of pembrolizumab and lenvatinib in pre-treated thymic carcinoma patients who have progressed after at least one line of platinum-based chemotherapy for advanced disease without having received any previous immunotherapy (previous bevacizumab allowed, but not sunitinib), and not amenable to curative-intent radical surgery and/or radiotherapy, regardless of PD-L1 status.

NCT ID: NCT03134118 Active, not recruiting - Thymic Carcinoma Clinical Trials

Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)

NIVOTHYM
Start date: April 11, 2018
Phase: Phase 2
Study type: Interventional

The aim of the phase II Nivothym study is to collect data on activity and toxicity of nivolumab therapy in patients with thymic carcinoma or type B3 thymoma that previously received a first platinum-based chemotherapy.

NCT ID: NCT02307500 Completed - Ovarian Cancer Clinical Trials

Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy

RESOUND
Start date: December 2014
Phase: Phase 2
Study type: Interventional

This is a single arm, single-stage, phase II trial to evaluate the activity of Regorafenib in patients with metastatic solid tumors (pancreatic cancer, ovarian cancer, melanoma, sarcoma, thymoma (type B2 - B3) and thymic carcinoma, who have progressed after standard therapy.